Fresenius SE & Co. KGaA (ETR:FRE)
44.23
-0.48 (-1.07%)
Sep 3, 2026, 5:35 PM CET
Fresenius SE & Co. KGaA Revenue
Fresenius SE & Co. KGaA had revenue of 5.95B EUR in the quarter ending June 30, 2026, with 5.22% growth. This brings the company's revenue in the last twelve months to 23.28B, up 3.38% year-over-year. In the year 2025, Fresenius SE & Co. KGaA had annual revenue of 22.87B with 4.19% growth.
Revenue (ttm)
23.28B
Revenue Growth
+3.38%
P/S Ratio
1.07
Revenue / Employee
130.44K
Employees
178,486
Market Cap
24.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.87B | 919.00M | 4.19% |
| Dec 31, 2024 | 21.95B | 887.00M | 4.21% |
| Dec 31, 2023 | 21.07B | -465.00M | -2.16% |
| Dec 31, 2022 | 21.53B | -15.99B | -42.61% |
| Dec 31, 2021 | 37.52B | 1.24B | 3.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Fresenius Medical Care AG | 19.43B |
| Sartorius Aktiengesellschaft | 3.58B |
| Drägerwerk AG & Co. KGaA | 3.57B |
| Fielmann Group AG | 2.46B |
| Carl Zeiss Meditec AG | 2.18B |
Fresenius SE & Co. KGaA News
- 13 days ago - Fresenius Cuts Fresenius Medical Care Stake, Raises About €300 Mln - Nasdaq
- 4 weeks ago - Fresenius Announces Climb In Q2 Bottom Line - Finanz Nachrichten
- 4 weeks ago - Fresenius Raises 2026 Earnings Guidance on Strong Performance - Wallstreet:Online
- 4 weeks ago - EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance - Wallstreet:Online
- 6 weeks ago - Fresenius establishes venture fund of more than €200 million to drive healthcare innovation - PRNewsWire
- 6 weeks ago - Shares in Generic-Drug Makers Fall After Trump's Tariff Plan - WSJ
- 1 year ago - Fresenius posts profit beat in first quarter, confirms outlook - Reuters
- 1 year ago - Fresenius SE Raises Guidance After Strong Kabi, Helios Performances - WSJ